-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4

Benzinga·06/23/2026 16:10:14
Listen to the news
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Overweight rating and announces Price Target of $4.